Microbot Medical

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Braintree, MA.

Proven Track Record of Numerous M&A and Strategic Collaboration Transactions Proven Track Record of Numerous M&A and Strategic Collaboration Transactions

Microbot Medical Appoints Aileen Stockburger to the Board of Directors

HINGHAM, Mass., March  03, 2020  (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Microbot Medical Inc. (NASDAQ: MBOT), please note that in the first paragraph the appointment of Eyal Morag, M.D. has been changed to commencing June 2020 and in the fourth paragraph Dr. Morag still currently serves as Chairman of Radiology at Assuta Ashdod Medical Center, Ashdod, Israel. The corrected release follows:

CORRECTING and REPLACING – Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer

HINGHAM, Mass., March  03, 2020  (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT), announced the appointment of Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer, effective immediately. In his new role, Dr. Morag will lead the development and execution of the clinical strategy of the Company’s technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future pipeline. Dr. Morag has been a member of the Company’s Scientific Advisory Board since November 2017 and will report directly to Harel Gadot, Chief Executive Officer, President, and Chairman.

Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer

As of late, it has definitely been a great time to be an investor Microbot Medical.

Microbot Medical Shares March Higher, Can It Continue?

Agile Therapeutics

Air Industries Group

Journey Medical Corp

Cassava Sciences Inc

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

HINGHAM, Mass., Jan.  08, 2020  (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received an official communication from the European Patent Office (EPO) regarding its intention to grant European Patent Application No. 11795301, covering the Company’s Self-Cleaning Shunt (SCS™). Globally, the Company now has 36 patents issued/allowed and 16 patent applications pending worldwide.

Microbot Medical Receives Intention to Grant from European Patent Office for a Patent Application Covering its Self-Cleaning Shunt

HINGHAM, Mass., Dec.  31, 2019  (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:  MBOT  ) closed its previously announced registered direct offering of 900,901 shares of its common stock at a purchase price of $11.10 per share for total gross proceeds of approximately $10.0 million, before deducting placement agent fees and offering expenses.

Microbot Medical Inc. Announces Closing of $10.0 Million Registered Direct Offering of Common Stock

HINGHAM, Mass., Dec.  30, 2019  (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 900,901 shares of its common stock, at a purchase price per share of $11.10, priced at-the-market under Nasdaq rules.

Microbot Medical Inc. Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Microbot Medical Inc. shares  slid 24% Friday, after the medical device company announced a $10 million registered direct offering priced at-the-market at $10.50, a discount to its closing price Thursday of $13.98.

Microbot Medical shares slide on news of dilutive equity offering but remains up 99% on the week

HINGHAM, Mass., Dec.  27, 2019  (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 952,383 shares of its common stock, at a purchase price per share of $10.50, priced at-the-market under Nasdaq rules.

Microbot Medical Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

HINGHAM, Mass., Dec.  27, 2019  (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase price of $10.50 per share for total gross proceeds of approximately $9.59 million, before deducting placement agent fees and offering expenses.

Microbot Medical Inc. Announces Closing of $9.59 Million Registered Direct Offering of Common Stock

HINGHAM, Mass., Dec.  26, 2019  (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 912,858 shares of its common stock, at a purchase price per share of $10.50, priced at-the-market under Nasdaq rules.

Microbot Medical Inc. Announces $9.59 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Microbot Medical Inc. (NASDAQ: MBOT) shares made a massive gain on Tuesday after the company revealed its Liberty system, which would be the world’s first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular procedures.

Will Microbot Medical’s Robotic Surgery System Be a Big Hit?

HINGHAM, Mass., Dec.  23, 2019  (GLOBE NEWSWIRE) --  Microbot Medical Inc. (NASDAQ: MBOT) today announced the revealing of LIBERTYTM, the world’s first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular procedures. The LIBERTY robotic system features a unique compact design with the capability to be operated remotely, reduce radiation exposure and physical strain to the physician, as well as the potential to eliminate the use of multiple consumables through its “One & Done” capabilities. Microbot is set to publicly display and demonstrate LIBERTY to investors, journalists and healthcare industry leaders on Monday, January 13, 2020, in San Francisco.

Microbot Medical to Unveil World’s First Fully Disposable Robotic System for Endovascular Procedures

HINGHAM, Mass., Oct.  30, 2019  (GLOBE NEWSWIRE) -- In an expansion of its significant global patent estate, Microbot Medical Inc. (Nasdaq: MBOT) announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 15/218,025, covering the Company’s TipCATTM technology platform. The allowed patent application is a Continuation of Patent No. 9,427,143, issued on August 30, 2016.

Microbot Receives Notice of Allowance for U.S. Patent Covering its TipCAT™ Technology Platform

Maintains Regulatory  Pre-Submission Timeline of the Self-Cleaning Shunt (SCS  TM )

Microbot Medical Announces Outcome of Annual Meeting of Shareholders

HINGHAM, Mass., Sept.  05, 2019  (GLOBE NEWSWIRE) -- At the upcoming Rodman & Renshaw Global Investment Conference, Harel Gadot, CEO, President and Chairman of Microbot Medical Inc. (Nasdaq: MBOT), will demonstrate a working prototype of the Company’s Self-Cleaning Shunt (SCS™).

Microbot Medical to Demonstrate a Working Prototype of its Self-Cleaning Shunt at the Rodman & Renshaw Annual Global Investment Conference

News for Microbot Medical Stock (MBOT)